Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

54.63USD
1:33am IST
Change (% chg)

$1.24 (+2.32%)
Prev Close
$53.39
Open
$54.25
Day's High
$54.66
Day's Low
$53.75
Volume
341,752
Avg. Vol
--
52-wk High
$54.95
52-wk Low
$41.73

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.92
Market Cap(Mil.): $113,967.40
Shares Outstanding(Mil.): 2,112.56
Dividend: 0.76
Yield (%): 1.42

Financials

  NVO.N Industry Sector
P/E (TTM): 36.99 40.70 41.18
EPS (TTM): 1.44 -- --
ROI: 59.19 16.89 16.23
ROE: 63.92 17.42 17.07
Search Stocks

European shares post 2015's biggest weekly fall despite Novo Nordisk surge

* FTSEurofirst 300 up 0.2 pct after losing 1.9 pct in two days

27 Mar 2015

European shares set for 2015's biggest weekly fall despite Novo Nordisk surge

* Euro zone shares recover as euro falls back (Recasts, adds quotes)

27 Mar 2015

Novo Nordisk surge buoys European shares after two-day slide

* Euro zone shares recover as euro falls back (Adds quote, detail, updates prices)

27 Mar 2015

Europe shares snap two-day slide; Novo Nordisk rallies

PARIS, March 27 - European stocks rose in early trade on Friday, halting a sharp two-day retreat as a renewed fall in the euro helped boost exporters' shares.

27 Mar 2015

Novo Nordisk surges on plan to resubmit rejected insulin in U.S.

- Denmark's Novo Nordisk is to resubmit its new insulin Tresiba to U.S. regulators based on interim analysis data from a clinical trial, bringing its biggest new drug hope closer to the world's top market.

27 Mar 2015

European shares snap two-day slide; Novo Nordisk rallies

PARIS, March 27 - European stocks rose in early trade on Friday, halting a sharp two-day retreat as a renewed fall in the euro currency helped boost the shares of exporting companies.

27 Mar 2015

Novo Nordisk filing move brings Tresiba closer to U.S. market

- Denmark's Novo Nordisk said on Thursday it had decided to submit interim analysis data from a clinical trial of its crucial new insulin drug Tresiba to U.S. regulators within the next month.

26 Mar 2015

UPDATE 1 -Novo Nordisk filing move brings Tresiba closer to U.S. market

March 26 - Denmark's Novo Nordisk said on Thursday it had decided to submit interim analysis data from a clinical trial of its crucial new insulin drug Tresiba to U.S. regulators within the next month.

26 Mar 2015

Novo Nordisk to submit interim data on Tresiba drug in U.S.

March 26 - Denmark's Novo Nordisk said on Thursday it had decided to submit interim analysis data from a clinical trial of its crucial new insulin drug Tresiba to U.S. regulators within the next month.

26 Mar 2015

BRIEF-Novo Nordisk to resubmit U.S. new drug applications for Tresiba and Ryzodeg

* Has decided to resubmit the new drug applications of Tresiba and Ryzodeg in the U.S.Source text for Eikon: Further company coverage: (Reporting By Ben Hirschler)

26 Mar 2015

Competitors

  Price Chg
Sanofi SA (SASY.PA) €92.93 --
Eli Lilly and Co (LLY.N) $71.53 -1.12

Earnings vs. Estimates

Search Stocks